Are CB2 Receptors a New Target for Schizophrenia Treatment?

Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptor...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in psychiatry Vol. 11; p. 587154
Main Authors Cortez, Isadora L, Rodrigues da Silva, Naielly, Guimarães, Francisco S, Gomes, Felipe V
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 30.10.2020
Subjects
cannabinoids
dopamine
endocannabinoid system
microglia
Psychiatry
psychosis
cannabinoids
endocannabinoid system
dopamine
microglia
psychosis
Online AccessGet full text

Cover

More Information
Summary:Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptors are now proposed to play a role in several brain processes related to schizophrenia, such as modulation of dopaminergic neurotransmission, microglial activation, and neuroplastic changes induced by stress. Here, we reviewed studies describing the involvement of the CB2 receptor in these processes and their association with the pathophysiology of schizophrenia. Taken together, these pieces of evidence indicate that CB2 receptor may emerge as a new target for the development of antipsychotic drugs.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Daniel Umbricht, Roche, Switzerland; Jorge Manzanares, Miguel Hernández University of Elche, Spain
Edited by: Sagnik Bhattacharyya, King's College London, United Kingdom
This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry
ISSN:1664-0640
1664-0640
DOI:10.3389/fpsyt.2020.587154